Divi’s Laboratories Managing Director Murali K. Divi is now the highest paid CEO in India’s listed pharmaceutical sector, taking home ₹100.26 crore in total remuneration in FY26. The payout was driven almost entirely by profit-linked commissions, highlighting a compensation model that closely aligns executive earnings with the company’s financial performance rather than fixed salaries.
An analysis of annual reports from nine leading listed pharmaceutical companies shows that executive compensation across the sector is increasingly tied to commissions, long-term incentives, and stock-based rewards, making year-on-year comparisons more complex. While Divi’s Laboratories topped the list by a wide margin, other major drugmakers such as Cipla, Zydus Lifesciences, Torrent Pharmaceuticals, and Lupin also reported substantial executive payouts.
Murali K. Divi Tops Pharma Executive Pay Chart
Murali K. Divi earned ₹100.26 crore during FY26, more than double the compensation of the next highest-paid executive in the industry.
Notably:
- ₹99.9 crore came from profit-linked commissions.
- Only ₹0.36 crore consisted of perquisites and allowances.
- There was effectively no fixed salary component.
The commission is calculated as a percentage of the company’s net profits under Section 197 of the Companies Act, 2013, meaning executive pay rises and falls alongside the company’s profitability rather than through negotiated salary increases.
Murali K. Divi’s FY26 Compensation
| Component | Amount |
|---|---|
| Total remuneration | ₹100.26 crore |
| Profit-linked commission | ₹99.9 crore |
| Perquisites & allowances | ₹0.36 crore |
| Fixed salary | Effectively nil |
Divi’s Leadership Pay Mirrors Company Performance
The profit-linked commission structure extends across Divi’s senior leadership.
Other executive directors also recorded remuneration increases of around 13%, reflecting a formula-based commission pool linked to the company’s earnings.
Top Executives at Divi’s Laboratories
| Executive | FY26 Remuneration |
|---|---|
| Murali K. Divi (Managing Director) | ₹100.26 crore |
| N. V. Ramana (Executive Director) | ₹51.20 crore |
| Kiran S. Divi (CEO & Whole-time Director) | ₹34.84 crore |
| Nilima Prasad Divi (Whole-time Director – Commercial) | ₹34.78 crore |
The near-identical percentage increase across senior executives suggests that remuneration is determined primarily by company profitability rather than individual salary negotiations.
How Other Pharma Executives Compare
Divi’s Laboratories led the industry by a considerable margin.
Among the other highest-paid executives:
- Umang Vohra, former MD and Global CEO of Cipla, earned ₹45.73 crore, though the figure included a one-time long-term incentive linked to his departure.
- Sharvil Patel, Managing Director of Zydus Lifesciences, received ₹45 crore.
- Samir Mehta, Executive Chairman of Torrent Pharmaceuticals, earned ₹36 crore, with most of his compensation also commission-based.
- Vinita Gupta, CEO of Lupin, received ₹26.69 crore.
Highest-Paid Pharma Executives in FY26
| Rank | Executive | Company | FY26 Pay |
|---|---|---|---|
| 1 | Murali K. Divi | Divi’s Laboratories | ₹100.26 crore |
| 2 | Umang Vohra | Cipla | ₹45.73 crore |
| 3 | Sharvil Patel | Zydus Lifesciences | ₹45.00 crore |
| 4 | Samir Mehta | Torrent Pharmaceuticals | ₹36.00 crore |
| 5 | Vinita Gupta | Lupin | ₹26.69 crore |
Different Compensation Models Across the Industry
The analysis highlights two distinct executive compensation approaches in India’s pharmaceutical sector.
Companies such as Divi’s Laboratories and Torrent Pharmaceuticals rely heavily on profit-linked commissions, allowing remuneration to move in tandem with company earnings.
Others, including Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Biocon, Lupin, and Mankind Pharma, use a more balanced mix of:
- Fixed salaries.
- Annual performance bonuses.
- Deferred long-term incentives.
- Employee Stock Option Plans (ESOPs) for eligible non-promoter executives.
Compensation Models
| Model | Characteristics |
|---|---|
| Profit-linked commissions | Pay directly tied to company profits |
| Fixed salary + incentives | Mix of salary, bonuses, and long-term rewards |
| ESOP-based incentives | Primarily available to non-promoter professional executives |
A Wider Trend in Indian Boardroom Pay
Sharp increases in top-deck remuneration are not limited to pharmaceuticals. Indian boards across sectors have been raising performance-linked pay as companies post stronger earnings, with recent disclosures showing Ashok Leyland’s CEO pay jumping 49% and HCLTech’s CEO pay rising 67% to $18.13 million. What sets Divi’s apart is the structure: where most listed companies use a base salary topped up with bonuses and stock, Divi’s pays its promoter-executives almost purely through a profit share.
That structure cuts both ways. In a strong year the payout scales with profits; in a weak year it can fall just as sharply, because there is no salary floor to protect it. For investors tracking the sector, the pay line therefore doubles as a read on earnings momentum at a time when Indian drugmakers are chasing new growth engines, including the GLP-1 opportunity in the domestic market.
What It Means for Corporate Governance
The findings illustrate how promoter-led pharmaceutical companies increasingly link executive compensation to business performance. Supporters argue that commission-based remuneration aligns management interests with shareholder value by rewarding sustained profitability.
However, the growing use of profit-linked commissions, deferred incentives, and stock-based compensation also makes executive pay packages more difficult to compare across companies and financial years, particularly when one-time incentives or retirement benefits are included.
Looking Ahead
Murali K. Divi’s ₹100.26 crore remuneration sets a new benchmark for executive compensation in India’s listed pharmaceutical industry, reflecting Divi’s Laboratories’ strong financial performance and its distinctive commission-based remuneration model. Unlike traditional salary-heavy packages, the company’s approach ties executive earnings almost entirely to profitability, resulting in significant upside during periods of robust growth.
As Indian pharmaceutical companies continue to expand globally and compete for leadership talent, executive compensation structures are likely to evolve further. Investors and governance experts will increasingly scrutinize how remuneration balances incentives, shareholder interests, and long-term value creation, particularly as profit-linked and equity-based pay become more common across the sector.
Frequently Asked Questions
Who is the highest paid CEO in India’s pharma sector?
Among India’s largest listed drugmakers, Divi’s Laboratories Managing Director Murali K. Divi was the highest paid in FY26 with ₹100.26 crore, more than double the next-highest package in the analysis of nine leading pharma companies.
Why is Murali K. Divi’s salary so high?
He draws effectively no fixed salary. Of the ₹100.26 crore, ₹99.9 crore came from a profit-linked commission calculated as a percentage of net profits under Section 197 of the Companies Act, 2013, with just ₹0.36 crore in perquisites and allowances.
Which other pharma CEOs are on the top-paid list for FY26?
Cipla’s former MD and Global CEO Umang Vohra at ₹45.73 crore, Zydus Lifesciences MD Sharvil Patel at ₹45 crore, Torrent Pharmaceuticals Executive Chairman Samir Mehta at ₹36 crore, and Lupin CEO Vinita Gupta at ₹26.69 crore.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
